百诚医药：楼金芳增持公司股份约93万股

Group 1 - The core point of the article is that Baicheng Pharmaceutical has completed a share buyback plan, with a total of approximately 930,000 shares acquired, representing 0.85% of the company's total equity, for a total investment of approximately RMB 50.31 million [1] - As of the first half of 2025, Baicheng Pharmaceutical's revenue composition is as follows: CRO business accounts for 86.22%, commercial production accounts for 10.28%, and CDMO business accounts for 3.5% [1] - The current market capitalization of Baicheng Pharmaceutical is RMB 5.9 billion [1]